Drug intelligence / Profile preview

LPT-305

Development stage: Preclinical
Lead developer: LitePharmTech
Modality: Small Molecules
Administration: Ophthalmic

Overview

LPT-305 is an incrementally modified drug (IMD) candidate currently in preclinical development by LitePharmTech. It is formulated as an ophthalmic solution for the treatment of ocular conditions. As an IMD, LPT-305 likely represents an improved formulation or delivery method of an existing pharmaceutical agent, aimed at enhancing therapeutic efficacy, safety, or patient compliance compared to standard treatments. Specific details regarding the active pharmaceutical ingredient or its molecular target have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on LPT-305.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LPT-305.

Explore the full profile